Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd.

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Special 250th anniversary designs offer a golden opportunity to grow the hobby and inspire the next generation of ...

Revenue: $6.3 million for the first quarter of fiscal 2026 (period ended June 30, 2025), up 7% sequentially and 35% year over ...

Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the 'Company”) today reported results for the first quarter fiscal year 2026, which ended June 29, 2025.

Discover key insights from Arcturus Therapeutics' Q2 2025 earnings call, featuring updates on CF and OTC programs, vaccine progress, and ...

Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the "Company") today reported results for the first quarter fiscal year 2026, which ended June 29, 2025. First ...

Q2 2025 Management View James V. Caruso, President and CEO, stated that Cellectar has made "significant strides across our ...

Q1 2026 Earnings Call Transcript August 8, 2025 Under Armour, Inc. misses on earnings expectations. Reported EPS is $0.02 EPS ...

Condor Energies Inc. ('Condor” or the 'Company”) (TSX:CDR), a Canadian based, internationally focused energy transition company focused on Central Asia is pleased to announce the release of its ...

Honda and Acura have a pattern of showing multiple stages of concepts, those that we would more traditionally think of as ...